ROIV News and Press, Roivant Sciences Ltd. From 02/13/23

Roivant Sciences press release ( NASDAQ: ROIV ): Q3 GAAP EPS of -$0.49 misses by $0.09 . Revenue of $17.05M (-30.0% Y/Y) beats by $2.27M . $9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions ...

$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launch VTAMA payor coverage significantly expanded, with 57% of commercial lives now covered ADORING 1 ...

Roivant Sciences ( NASDAQ: ROIV ) prices an upsized underwritten public offering of 26.66M shares at a price of $7.50 per share. The gross proceeds are expected to be $200M. Underwriters have a 30-day option to purchase up to an additional ~4M shares on the same terms and cond...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares ...

Roivant Sciences ( NASDAQ: ROIV ) on Wednesday announced that it has commenced an underwritten public offering of $150 million of common shares. Roivant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares. All of the...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters a 30-day opt...

Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ET Roivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTO...

The following slide deck was published by Roivant Sciences Ltd. in conjunction with this event. For further details see: Roviant Sciences (ROIV) Presents At 41st Annual Healthcare Conference - Slideshow

U.K.-based biotech Roivant Sciences ( NASDAQ: ROIV ) announced Wednesday that its Phase 2b trial for subcutaneous ulcerative colitis therapy RVT-3101 generated statistically significant and clinically meaningful efficacy results at each dose level. The 52-week TUSCANY-2 trial involved...

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose ...